Explore

Companies

Drugs

About·Data Management·Terms·Privacy

Stay informed

© 2026 VivoSeq. All rights reserved.

MRTX849

Phase 3Small molecule

MMirati Therapeutics Inc.

MRTX849 is one of 68 small molecule programs targeting Advanced Cancer. It is currently in Phase 3.

3

Indications

10

Total Trials

4

Active Trials

67

Competitors

Pipeline

Status by Indication[3][1]

Indication

Advanced CancerActive, not recruiting

Colon CancerActive, not recruiting

Metastatic Non Small Cell Lung CancerActive, not recruiting

Advanced CancerPreclinical

Active, not recruiting

Colon CancerPhase 1

Active, not recruiting

Metastatic Non Small Cell Lung CancerPhase 3

Active, not recruiting

Competition

Competitive Landscape

52 competitors in Advanced Cancer

#DrugCompanyPhaseTrials

Taxol

Keytruda

Opdivo

Bristol-Myers Squibb

T-Dxd

Herceptin

Verzenio

Elunate

Torisel

PPrism Pharmaceuticals

Paraplatin

Faslodex

FFresenius Kabi USA, LLC

Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.

Timeline

Expected Milestones

Q4 2026

PreclinicalActive, not recruiting

Advanced Cancer

NCT03785249

Q3 2027

Phase 1Active, not recruiting

Colon Cancer

NCT05722327

Clinical

Trials by Indication[1]

Patients With Advanced Solid Tumors2 trials

The Clinical Trial to Evaluate the Pharmacokinetics and Safety of MRTX849 in Patients With Advanced Solid Tumors

Unknown status·ZZai Lab (Shanghai) Co., Ltd.·Phase 1·NCT05263986·22 enrolled

Adagrasib in Combination With Palbociclib in Patients With Advanced Solid Tumors (KRYSTAL-16)

Completed·MMirati Therapeutics Inc.·Phase 1·NCT05178888·11 enrolled

Cancer2 trials

Adagrasib in Combination With BI 1701963 in Patients With Cancer (KRYSTAL 14)

Terminated·MMirati Therapeutics Inc.·Phase 1·NCT04975256·7 enrolled

Adagrasib in Combination With TNO155 in Patients With Cancer (KRYSTAL 2)

Completed·MMirati Therapeutics Inc.·Phase 1·NCT04330664·86 enrolled

Pancreatic Cancer1 trial

Phase Ib Trial of the KRASG12C Inhibitor Adagrasib (MRTX849) in KRAS G12C Mutant Metastatic Pancreatic Cancer Patients

Withdrawn·MM.D. Anderson Cancer Center·Phase 1·NCT05634525

Solid Tumors1 trial

A Phase 1 Study of MRTX0902 in Solid Tumors With Mutations in the KRAS MAPK Pathway

Terminated·MMirati Therapeutics Inc.·Phase 1·NCT05578092·64 enrolled

Advanced Colorectal Cancer1 trial

A Randomized Phase 3 Study of MRTX849 in Combination With Cetuximab Versus Chemotherapy in Patients With Advanced Colorectal Cancer With KRAS G12C Mutation With Disease Progression On or After Standard First-Line Therapy

Active, not recruiting· Bristol-Myers Squibb logo

Bristol-Myers Squibb·Phase 3·NCT04793958·461 enrolled

3 more indications

Colon Cancer1 trial

Phase I Trial of Adagrasib (MRTX849) in Combination With Cetuximab and Irinotecan in Patients With Colorectal Cancer

Active, not recruiting·MM.D. Anderson Cancer Center·Phase 1·NCT05722327·24 enrolled

Metastatic Non Small Cell Lung Cancer1 trial

A Randomized Phase 3 Study of MRTX849 Versus Docetaxel in Patients With Previously Treated Non-Small Cell Lung Cancer With KRAS G12C Mutation

Active, not recruiting·MMirati Therapeutics Inc.·Phase 3·NCT04685135·453 enrolled

Advanced Cancer1 trial

A Phase 1/2 Multiple Expansion Cohort Trial of MRTX849 in Patients With Advanced Solid Tumors With KRAS G12C Mutation KRYSTAL-1

Active, not recruiting·MMirati Therapeutics Inc.·Preclinical·NCT03785249·731 enrolled

Sources

References

[1]
ClinicalTrials.gov — 10 trial records for MRTX849. U.S. National Library of Medicine, National Institutes of Health.
[2]
ChEMBL — MRTX849 compound record. European Bioinformatics Institute (EMBL-EBI).
[3]
Open Targets Platform — Drug–disease associations for MRTX849. EMBL-EBI & Wellcome Sanger Institute.
[4]
SEC EDGAR — Mirati Therapeutics Inc. company filings. U.S. Securities and Exchange Commission.

Details

Drug Info

Quick Facts

Modality: Small molecule[2]
Highest Phase: Phase 3[1]
Company: MMirati Therapeutics Inc.

Related News